
Deborah P M Symmons

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6523001/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.5	2,994
3	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 363-369.	6.7	2,042
4	Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. Science, 2007, 316, 1336-1341.	6.0	2,040
5	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology, 2013, 133, 377-385.	0.3	1,827
6	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	9.4	1,298
7	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 325-331.	0.5	1,157
8	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 2017, 76, 17-28.	0.5	918
9	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
10	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2006, 54, 2368-2376.	6.7	694
11	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases, 2010, 69, 522-528.	0.5	606
12	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology, 2011, 50, 124-131.	0.9	564
13	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	9.4	558
14	Predictors of response to anti-TNF-Â therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2006, 45, 1558-1565.	0.9	533
15	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2007, 56, 2905-2912.	6.7	522
16	Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis and Rheumatism, 2007, 56, 13-20.	6.7	379
17	THE INCIDENCE OF RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER. Rheumatology, 1994, 33, 735-739.	0.9	377
18	Rheumatoid arthritis association at 6q23. Nature Genetics, 2007, 39, 1431-1433.	9.4	361

2

#	Article	IF	CITATIONS
19	Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care-based incident case-control study in Norfolk, England. Arthritis and Rheumatism, 1997, 40, 1955-1961.	6.7	337
20	Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis and Rheumatism, 2002, 46, 2010-2019.	6.7	328
21	Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nature Reviews Rheumatology, 2011, 7, 399-408.	3.5	320
22	Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis and Rheumatism, 2007, 56, 2896-2904.	6.7	292
23	Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritis. Nature Genetics, 2009, 41, 1319-1324.	9.4	282
24	Low back pain in schoolchildren: occurrence and characteristics. Pain, 2002, 97, 87-92.	2.0	275
25	Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: metaâ€analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiology and Drug Safety, 2011, 20, 119-130.	0.9	259
26	Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort. Arthritis and Rheumatism, 2005, 52, 2293-2299.	6.7	256
27	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246
28	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 69-74.	0.5	240
29	Predictors of Low Back Pain in British Schoolchildren: A Population-Based Prospective Cohort Study. Pediatrics, 2003, 111, 822-828.	1.0	239
30	Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Practice and Research in Clinical Rheumatology, 2002, 16, 707-722.	1.4	229
31	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases, 2013, 72, 211-216.	0.5	224
32	Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis and Rheumatism, 2007, 56, 2143-2149.	6.7	214
33	CAUSE OF DEATH IN RHEUMATOID ARTHRITIS. Rheumatology, 1984, 23, 92-99.	0.9	212
34	The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ: British Medical Journal, 2004, 329, 948.	2.4	203
35	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2009, 68, 209-215.	0.5	200
36	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 583-589.	0.5	188

#	Article	IF	CITATIONS
37	Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Archives of Disease in Childhood, 2003, 88, 12-17.	1.0	187
38	Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2010, 69, 1086-1091.	0.5	185
39	Neoplasms of the immune system in rheumatoid arthritis. American Journal of Medicine, 1985, 78, 22-28.	0.6	178
40	Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Research and Therapy, 2009, 11, R52.	1.6	173
41	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1810-1814.	0.5	173
42	Active Exercise, Education, and Cognitive Behavioral Therapy for Persistent Disabling Low Back Pain. Spine, 2007, 32, 1578-1585.	1.0	169
43	Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. Arthritis Care and Research, 2010, 62, 755-763.	1.5	168
44	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis and Rheumatism, 2002, 46, 906-912.	6.7	162
45	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1087-1093.	0.5	162
46	Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis and Rheumatism, 2008, 58, 359-369.	6.7	161
47	Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 11-16.	1.0	161
48	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 823-826.	0.5	154
49	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis and Rheumatism, 2003, 48, 46-53.	6.7	152
50	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. Annals of the Rheumatic Diseases, 2010, 69, 1589-1595.	0.5	152
51	ICF Core Sets for rheumatoid arthritis. Journal of Rehabilitation Medicine, 2004, 36, 87-93.	0.8	149
52	Dietary risk factors for the development of inflammatory polyarthritis: Evidence for a role of high level of red meat consumption. Arthritis and Rheumatism, 2004, 50, 3804-3812.	6.7	147
53	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2013, 72, 229-234.	0.5	146
54	Mortality in established rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2007, 21, 871-883.	1.4	140

#	Article	IF	CITATIONS
55	Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety. Annals of the Rheumatic Diseases, 2004, 63, 1538-1543.	0.5	139
56	Estimating the incidence of rheumatoid arthritis: Trying to hit a moving target?. Arthritis and Rheumatism, 1999, 42, 1339-1346.	6.7	136
57	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2006, 54, 1786-1794.	6.7	136
58	Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Annals of the Rheumatic Diseases, 2010, 69, 683-688.	0.5	135
59	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. Journal of Investigative Dermatology, 2015, 135, 2189-2197.	0.3	132
60	Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 308-312.	0.5	127
61	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 654-660.	0.5	122
62	National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. Journal of Rheumatology, 2003, 30, 958-65.	1.0	122
63	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. JAMA - Journal of the American Medical Association, 2015, 313, 1645.	3.8	119
64	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology, 2013, 52, 91-98.	0.9	116
65	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2013, 72, 1315-1320.	0.5	116
66	European biologicals registers: methodology, selected results and perspectives. Annals of the Rheumatic Diseases, 2009, 68, 1240-1246.	0.5	114
67	Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register. Arthritis Care and Research, 2014, 66, 1296-1301.	1.5	113
68	NATURAL REMISSION IN INFLAMMATORY POLYARTHRITIS: ISSUES OF DEFINITION AND PREDICTION. Rheumatology, 1996, 35, 1096-1100.	0.9	112
69	Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 697-705.	0.9	112
70	What effects might anti-TNFÂ treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFÂ in cardiovascular pathophysiology. Annals of the Rheumatic Diseases, 2007, 66, 1132-1136.	0.5	107
71	Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 563-570.	0.9	107
72	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2012, 71, 869-874.	0.5	107

Deborah P M Symmons

#	Article	IF	CITATIONS
73	Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. Annals of the Rheumatic Diseases, 2004, 63, 843-847.	0.5	106
74	Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population register. Arthritis and Rheumatism, 2006, 54, 2701-2702.	6.7	106
75	Cognitive Behavior Therapy, Exercise, or Both for Treating Chronic Widespread Pain. Archives of Internal Medicine, 2012, 172, 48.	4.3	106
76	The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis and Rheumatism, 2001, 44, 323-330.	6.7	105
77	Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Annals of the Rheumatic Diseases, 2010, 69, 503-509.	0.5	104
78	Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study. Seminars in Arthritis and Rheumatism, 1997, 26, 817-823.	1.6	102
79	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis and Rheumatism, 2006, 54, 2963-2969.	6.7	101
80	Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: Results from a large, population-based study. Arthritis and Rheumatism, 1999, 42, 757-762.	6.7	97
81	Dietary Î ² -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. American Journal of Clinical Nutrition, 2005, 82, 451-455.	2.2	97
82	Dietary Î ² -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. American Journal of Clinical Nutrition, 2005, 82, 451-455.	2.2	91
83	Modifiable risk factors for RA: prevention, better than cure?. Rheumatology, 2012, 51, 499-512.	0.9	90
84	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.5	88
85	Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. Journal of Rheumatology, 2008, 35, 883-90.	1.0	87
86	Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care and Research, 2012, 64, 1108-1115.	1.5	81
87	Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Annals of the Rheumatic Diseases, 2009, 68, 367-372.	0.5	80
88	Modest Association of Joint Hypermobility With Disabling and Limiting Musculoskeletal Pain: Results From a Largeâ€6cale General Population–Based Survey. Arthritis Care and Research, 2013, 65, 1325-1333.	1.5	79
89	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology, 2013, 52, 1754-1757.	0.9	79
90	Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis and Rheumatism, 2001, 44, 1033-1042.	6.7	77

#	Article	IF	CITATIONS
91	Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?. Annals of the Rheumatic Diseases, 2009, 68, 57-62.	0.5	77
92	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology, 2011, 50, 117-123.	0.9	77
93	The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis and Rheumatism, 1999, 42, 2174-2183.	6.7	76
94	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis and Rheumatism, 2001, 44, 1998-2008.	6.7	75
95	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.78	4314 rgBT 0.5	/Overlock 10 75
96	The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. Journal of Rheumatology, 2015, 42, 1448-1454.	1.0	75
97	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1570-1577.	0.9	73
98	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Research and Therapy, 2018, 20, 147.	1.6	73
99	No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2010, 62, 3145-3153.	6.7	72
100	Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE, 2019, 14, e0201196.	1.1	72
101	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	1.6	71
102	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology, 2015, 54, 1780-1791.	0.9	69
103	Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. Arthritis and Rheumatism, 2001, 44, 1248-1253.	6.7	68
104	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology, 2008, 47, 1000-1005.	0.9	67
105	Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. Journal of Rheumatology, 2012, 39, 240-246.	1.0	67
106	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology, 2016, 55, 2033-2039.	0.9	67
107	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis and Rheumatism, 2005, 52, 3596-3602.	6.7	65
108	Twenty‥ear Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis and Rheumatology, 2017, 69, 1566-1575.	2.9	63

#	Article	IF	CITATIONS
109	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with antiâ€TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 1831-1834.	0.5	62
110	Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2006, 66, 486-492.	0.5	60
111	Are Lipid Ratios Less Susceptible to Change With Systemic Inflammation Than Individual Lipid Components in Patients With Rheumatoid Arthritis?. Angiology, 2011, 62, 167-175.	0.8	60
112	Anti-tumor necrosis factor ? therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis and Rheumatism, 2004, 50, 1703-1706.	6.7	59
113	Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts. Seminars in Arthritis and Rheumatism, 2014, 44, 131-144.	1.6	59
114	THE PREVALENCE OF DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS IN WHITES AND INDIAN ASIAN IMMIGRANTS IN LEICESTER CITY, UK. Rheumatology, 1992, 31, 679-682.	0.9	58
115	The role of diet in susceptibility to rheumatoid arthritis: a systematic review. Journal of Rheumatology, 2004, 31, 1310-9.	1.0	58
116	The influence of age at symptom onset and length of followup on mortality in patients with recentâ€onset inflammatory polyarthritis. Arthritis and Rheumatism, 2008, 58, 985-989.	6.7	56
117	The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 2330-6.	1.0	55
118	Predicting persistent disabling low back pain in general practice: a prospective cohort study. British Journal of General Practice, 2006, 56, 334-41.	0.7	54
119	Environmental factors and the outcome of rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2003, 17, 717-727.	1.4	53
120	The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology, 2008, 47, 1441-1443.	0.9	53
121	The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. Journal of Rheumatology, 2008, 35, 592-602.	1.0	52
122	The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Quality of Life Research, 2009, 18, 1195-205.	1.5	51
123	Multivariate metaâ€analysis of mixed outcomes: a Bayesian approach. Statistics in Medicine, 2013, 32, 3926-3943.	0.8	51
124	Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Research and Therapy, 2014, 16, 483.	1.6	51
125	THE INCIDENCE OF RHEUMATOID VASCULITIS IN THE NORWICH HEALTH AUTHORITY. Rheumatology, 1994, 33, 832-833.	0.9	50
126	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology, 2009, 48, 1323-1327.	0.9	50

#	Article	IF	CITATIONS
127	Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1095-1098.	0.5	48
128	What is the natural history of rheumatoid arthritis?. Best Practice and Research in Clinical Rheumatology, 2001, 15, 27-48.	1.4	47
129	Looking back: rheumatoid arthritis—aetiology, occurrence and mortality. Rheumatology, 2005, 44, iv14-iv17.	0.9	45
130	Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open, 2017, 3, e000473.	1.8	45
131	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapyâ€induced lymphopenia: Twelveâ€year outcomes. Arthritis and Rheumatism, 2008, 58, 370-375.	6.7	44
132	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2011, 50, 1341-1342.	0.9	43
133	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, 285.	1.6	43
134	Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. Journal of Public Health, 2004, 26, 277-284.	1.0	42
135	Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. Journal of Rheumatology, 2003, 30, 902-4.	1.0	42
136	Does diet have a role in the aetiology of rheumatoid arthritis?. Proceedings of the Nutrition Society, 2004, 63, 137-143.	0.4	41
137	Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2010, 69, 689-695.	0.5	41
138	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2016, 75, 1139-1144.	0.5	41
139	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 241-250.	1.0	40
140	Body Fat Percentage, Waist Circumference, and Obesity As Risk Factors for Rheumatoid Arthritis: A Danish Cohort Study. Arthritis Care and Research, 2019, 71, 777-786.	1.5	40
141	Title is missing!. Spine, 2003, 28, 1195-1202.	1.0	39
142	Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. Arthritis Care and Research, 2012, 64, 1225-1232.	1.5	39
143	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology, 2004, 43, 731-736.	0.9	38
144	Influence of inflammatory polyarthritis on cancer incidence and survival: Results from a community-based prospective study. Arthritis and Rheumatism, 2007, 56, 790-798.	6.7	38

#	Article	IF	CITATIONS
145	Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care and Research, 2010, 62, 664-675.	1.5	38
146	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open, 2018, 4, e000596.	1.8	38
147	Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis. Journal of Clinical Epidemiology, 2000, 53, 988-996.	2.4	36
148	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 389-393.	0.5	36
149	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 2015, 74, 963-969.	0.5	36
150	Outcome in patients hospitalised for psoriatic arthritis. Clinical Rheumatology, 1989, 8, 261-265.	1.0	35
151	Disease assessment indices: activity, damage and severity. Bailliere's Clinical Rheumatology, 1995, 9, 267-285.	1.0	35
152	1 What is early rheumatoid arthritis?: definition and diagnosis. Bailliere's Clinical Rheumatology, 1997, 11, 13-26.	1.0	35
153	Classification criteria for rheumatoid arthritistime to abandon rheumatoid factor?. Rheumatology, 2007, 46, 725-726.	0.9	35
154	Lymphoma and rheumatoid arthritisagain. Rheumatology, 2007, 46, 1-2.	0.9	34
155	Association of functional outcome with both personal―and areaâ€ŀevel socioeconomic inequalities in patients with inflammatory polyarthritis. Arthritis and Rheumatism, 2009, 61, 1297-1304.	6.7	34
156	Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2014, 73, 1677-1682.	0.5	34
157	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Annals of the Rheumatic Diseases, 2013, 72, 461-462.	0.5	33
158	Smokingâ€Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink. Arthritis Care and Research, 2016, 68, 1598-1606.	1.5	33
159	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2019, 58, 80-85.	0.9	33
160	The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2011, 50, 78-84.	0.9	32
161	Association Between Genetic Variation in <i>FOXO3</i> and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2629-2636.	2.9	32
162	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Annals of the Rheumatic Diseases, 2014, 73, 684-690.	0.5	31

#	Article	IF	CITATIONS
163	Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary careâ€based inception cohort of patients. Rheumatology, 2002, 41, 246-252.	0.9	30
164	Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies. Arthritis Care and Research, 2010, 62, 345-353.	1.5	30
165	Reduction of longâ€ŧerm disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2011, 63, 945-952.	1.5	30
166	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. Annals of the Rheumatic Diseases, 2013, 72, 143-144.	0.5	30
167	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2013, 52, 1905-1913.	0.9	30
168	Risk of lymphoma in patients with RA treated with anti-TNFÂ agents. Annals of the Rheumatic Diseases, 2005, 64, 657-658.	0.5	29
169	Bone Health in Adult Men and Women with a History of Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 1689-1693.	1.0	29
170	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	1.8	29
171	Why Do Patients with Inflammatory Arthritis Often Score States "Worse than Death―on the EQ-5D? An Investigation of the EQ-5D Classification System. Value in Health, 2009, 12, 1026-1034.	0.1	28
172	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health and Quality of Life Outcomes, 2010, 8, 21.	1.0	28
173	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2016, 55, 1601-1609.	0.9	28
174	Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Research and Therapy, 2018, 20, 50.	1.6	28
175	Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Research and Therapy, 2006, 8, 214.	1.6	27
176	Learned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis. Rheumatology, 2013, 52, 1233-1238.	0.9	27
177	Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time?. Journal of Rheumatology, 2014, 41, 1590-1599.	1.0	27
178	Knee pain in older adults: the latest musculoskeletal "epidemic". Annals of the Rheumatic Diseases, 2001, 60, 89-90.	0.5	26
179	Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. British Journal of Rheumatology, 2002, 41, 767-774.	2.5	26
180	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Research and Therapy, 2011, 13, R159.	1.6	26

#	Article	IF	CITATIONS
181	Primary careâ€based screening for cardiovascular risk factors in patients with psoriasis. British Journal of Dermatology, 2016, 175, 348-356.	1.4	26
182	Does early rheumatoid arthritis exist?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 37-53.	1.4	25
183	Patient-reported improvements in health are maintained 2 years after completing a short course of cognitive behaviour therapy, exercise or both treatments for chronic widespread pain: long-term results from the MUSICIAN randomised controlled trial. RMD Open, 2015, 1, e000026-e000026.	1.8	25
184	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	1.8	25
185	Vasculitis of the gall bladder in rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology, 1987, 6, 287-289.	1.0	24
186	Health state utility values: A description of their development and application for rheumatic diseases. Arthritis and Rheumatism, 2008, 59, 1018-1026.	6.7	24
187	The world of biologics. Lupus, 2006, 15, 122-126.	0.8	23
188	Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. Rheumatology, 2010, 49, 1943-1948.	0.9	23
189	What is the outcome of RA in 2011 and can we predict it?. Best Practice and Research in Clinical Rheumatology, 2011, 25, 485-496.	1.4	23
190	HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2618-2628.	2.9	23
191	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212426.	0.5	23
192	Influence of age and sex on functional outcome over time in a cohort of patients with recentâ€onset inflammatory polyarthritis: Results from the Norfolk arthritis register. Arthritis Care and Research, 2011, 63, 1745-1752.	1.5	22
193	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. Journal of Rheumatology, 2013, 40, 144-156.	1.0	22
194	Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 1089-1096.	0.9	22
195	The relationship between oral contraceptive use and functional outcome in women with recentâ€onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis and Rheumatism, 2011, 63, 2183-2191.	6.7	21
196	What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. Arthritis Research and Therapy, 2016, 18, 282.	1.6	21
197	The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2010, 69, 1834-1837.	0.5	20
198	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2017, 4, 309-332.	1.1	20

#	Article	IF	CITATIONS
199	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, 1533-1540.	0.9	20
200	Life events and the onset of rheumatoid arthritis. Journal of Psychosomatic Research, 1994, 38, 837-847.	1.2	19
201	Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis. Arthritis and Rheumatism, 2003, 48, 3615-3616.	6.7	19
202	An evaluation of the decision tree format of the American College of Rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study. Arthritis and Rheumatism, 2005, 52, 2277-2283.	6.7	19
203	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2013, 65, 122-126.	1.5	19
204	Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. Annals of the Rheumatic Diseases, 2016, 75, 317-320.	0.5	19
205	Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology, 2007, 46, 1819-1823.	0.9	18
206	Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1660-1664.	0.5	18
207	In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2011, 70, 1428-1432.	0.5	18
208	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology, 2011, 50, 146-151.	0.9	18
209	Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature. Rheumatology, 2012, 51, 216-229.	0.9	18
210	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Research and Therapy, 2012, 14, R109.	1.6	18
211	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.5	18
212	Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. Journal of Rheumatology, 2004, 31, 442-7.	1.0	18
213	Selfâ€reported pain severity is associated with a history of coronary heart disease. European Journal of Pain, 2015, 19, 167-175.	1.4	17
214	Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 945-9.	1.0	17
215	Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis. Current Opinion in Rheumatology, 2013, 25, 157-163.	2.0	16
216	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	1.5	16

#	Article	IF	CITATIONS
217	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1337-1345.	2.9	16
218	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.5	16
219	Risk of <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor 1±: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. Rheumatology, 2016, 55, 1336-1337.	0.9	15
220	Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models. Pharmacoeconomics, 2014, 32, 109-134.	1.7	14
221	Same question, different answers: a comparison of global health assessments using visual analogue scales. Quality of Life Research, 2009, 18, 1285-1292.	1.5	13
222	Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care and Research, 2010, 62, 676-682.	1.5	13
223	Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis. Value in Health, 2014, 17, 109-115.	0.1	13
224	The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication. Current Rheumatology Reports, 2015, 17, 31.	2.1	13
225	Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS ONE, 2019, 14, e0215999.	1.1	13
226	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology, 2022, 61, 3930-3938.	0.9	13
227	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". Journal of Rheumatology, 2006, 33, 552-7.	1.0	13
228	Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2007, 66, 658-663.	0.5	12
229	Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2011, 70, 642-645.	0.5	12
230	UK rheumatology consultant workforce provision 2007–9: results from the BSR/Arthritis Research UK Consultant Workforce Register. Clinical Medicine, 2011, 11, 119-124.	0.8	12
231	Cardiovascular risk and its modification in patients with connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 81-94.	1.4	12
232	Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2018, 48, 384-398.	1.6	12
233	Short-term effects of antirheumatic drugs. Bailliere's Clinical Rheumatology, 1992, 6, 117-140.	1.0	11
234	Multiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2012, 71, 528-533.	0.5	11

#	Article	IF	CITATIONS
235	The role of genetic polymorphisms regulating vitamin D levels in rheumatoid arthritis outcome: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 2014, 73, 1430-1433.	0.5	11
236	Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink. RMD Open, 2017, 3, e000506.	1.8	11
237	The NOAR Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular damage in patients with early inflammatory polyarthritis including rheumatoid arthritis. British Journal of Rheumatology, 2004, 43, 1519-1525.	2.5	10
238	An update on UK rheumatology consultant workforce provision: the BSR/ARC Workforce Register 2005-07: assessing the impact of recent changes in NHS provision. Rheumatology, 2008, 47, 1065-1069.	0.9	10
239	Editorial: Do We Need a Diseaseâ€Specific Cardiovascular Risk Calculator for Patients With Rheumatoid Arthritis?. Arthritis and Rheumatology, 2015, 67, 1990-1994.	2.9	10
240	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet, The, 2015, 385, S44.	6.3	10
241	Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years. Rheumatology, 2017, 56, 1510-1517.	0.9	10
242	Selection of study population in the development of rheumatic disease criteria: comment on the article by the american college of rheumatology diagnostic and therapeutic criteria committee. Arthritis and Rheumatism, 1995, 38, 722-722.	6.7	9
243	CLINICAL AUDIT: CHANGING PATTERNS OF RHEUMATOLOGY MANPOWER AND PRACTICE IN THE UK IN THE 1990s. Rheumatology, 1996, 35, 483-487.	0.9	9
244	The burden of rheumatic disease. Medicine, 2006, 34, 333-335.	0.2	9
245	Developments in rheumatology consultant manpower provision: the BSR/arc Workforce Register 2003–05. Rheumatology, 2006, 45, 1416-1421.	0.9	8
246	Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 787-788.	0.5	8
247	Epidemiology research in rheumatology—progress and pitfalls. Nature Reviews Rheumatology, 2015, 11, 631-638.	3.5	8
248	Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2015, 74, 2099-2102.	0.5	8
249	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open, 2016, 2, e000273.	1.8	8
250	RHEUMATOLOGY MANPOWER IN THE 1990s. Rheumatology, 1991, 30, 119-122.	0.9	7
251	The overall status in rheumatoid arthritis (OSRA) measurefurther evidence to support its use in clinical practice. Rheumatology, 2007, 46, 849-855.	0.9	7
252	The burden of musculoskeletal conditions. Medicine, 2014, 42, 190-192.	0.2	7

#	Article	IF	CITATIONS
253	Methodological issues in conducting and analyzing longitudinal observational studies in rheumatoid arthritis. Journal of rheumatology Supplement, The, 2004, 69, 30-4.	2.2	7
254	MEASURING OUTCOME IN RHEUMATOID ARTHRITIS—WHICH MEASURES ARE SUITABLE FOR ROUTINE CLINICAL USE?. Rheumatology, 1995, 34, 802-804.	0.9	6
255	Anti-tumour necrosis factor therapy: can we afford it?. Annals of the Rheumatic Diseases, 2005, 64, 969-970.	0.5	6
256	The burden of musculoskeletal conditions. Medicine, 2010, 38, 126-128.	0.2	6
257	Delivery of paediatric rheumatology care in the UK—the projected shortfall. Clinical Rheumatology, 2011, 30, 679-683.	1.0	6
258	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and Drug Safety, 2015, 24, 1121-1132.	0.9	6
259	Joint sepsis as a complication of sero-negative arthritis. Clinical Rheumatology, 1985, 4, 51-54.	1.0	5
260	A PATIENT WITH RHEUMATOID ARTHRITIS AND LYMPHOMA. Rheumatology, 1992, 31, 107-112.	0.9	5
261	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. Annals of the Rheumatic Diseases, 2013, 72, 1517-1523.	0.5	5
262	2010 ACR/EULAR classification criteria for rheumatoid arthritis predict increased mortality in patients with early arthritis: results from the Norfolk Arthritis Register. Rheumatology, 2013, 52, 1141-1142.	0.9	5
263	Direct Health Costs of Inflammatory Polyarthritis 10 Years after Disease Onset: Results from the Norfolk Arthritis Register. Journal of Rheumatology, 2015, 42, 794-798.	1.0	5
264	The role of specialists in managing established rheumatoid arthritis. Rheumatology, 2007, 47, 237-238.	0.9	4
265	The Role of Anti–Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?. Seminars in Oncology, 2010, 37, 11-19.	0.8	4
266	P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. Rheumatology, 2014, 53, i34-i35.	0.9	4
267	A Study of Lymph Node Lymphocytes in Rheumatoid Arthritis. , 1985, 186, 1027-1032.		4
268	Reconciling subject differences in recruitment to clinical trials and clinical practice. Journal of Rheumatology, 2005, 32, 2475-6.	1.0	4
269	Reply to letter by Lippi et al commenting on the relationship between serum vitamin D levels and levels of inflammation markers. Arthritis and Rheumatism, 2008, 58, 1882-1882.	6.7	3
270	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. Journal of Biopharmaceutical Statistics, 2013, 23, 461-476.	0.4	3

#	Article	IF	CITATIONS
271	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, 1429-1430.	0.5	3
272	Influence of arthritis and non-arthritis related factors on areal bone mineral density (BMDa) in women with longstanding inflammatory polyarthritis: a primary care based inception cohort. BMC Musculoskeletal Disorders, 2010, 11, 106.	0.8	2
273	Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis. Journal of Rheumatology, 2011, 38, 429-433.	1.0	2
274	Musculoskeletal researchopportunities for all?. Rheumatology, 2012, 51, 1527-1528.	0.9	2
275	Response to: †Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al. Annals of the Rheumatic Diseases, 2017, 76, e4-e4.	0.5	2
276	Influence of Inflammatory Polyarthritis on Quantitative Heel Ultrasound Measurements. BMC Musculoskeletal Disorders, 2012, 13, 133.	0.8	1
277	How Do We Classify Rheumatoid Arthritis in Established Disease — Can We Apply the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria?. Journal of Rheumatology, 2014, 41, 2347-2351.	1.0	1
278	Response to: â€~Evaluation of the association between anticarbamylated protein antibodies and longitudinal course of functional ability in rheumatoid arthritis' by Ajeganova <i>et al</i> . Annals of the Rheumatic Diseases, 2016, 75, e15-e15.	0.5	1
279	153. ASSESSMENT OF PREDICTORS OF AND OUTCOMES FOLLOWING ORTHOPAEDIC JOINT SURGERY OVER 2 YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS RECRUITED TO THE NORFOLK ARTHRITIS REGISTER. Rheumatology, 2017, 56, .	.0 0.9	1
280	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2019, 59, 559-567.	0.9	1
281	Commentary: Juvenile idiopathic arthritis—issues of definition and causation. International Journal of Epidemiology, 2005, 34, 671-672.	0.9	0
282	Ischemic stroke: Another feature of accelerated atherosclerosis in rheumatoid arthritis?. Arthritis and Rheumatism, 2008, 59, 1051-1053.	6.7	0
283	Epidemiology and rheumatology: how can epidemiologists affect treatment strategies?. Nature Clinical Practice Rheumatology, 2008, 4, 1-1.	3.2	0
284	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. Rheumatology, 2010, 49, 1794-1794.	0.9	0
285	OP0232â€Long-Term Effects of Cognitive Behaviour Therapy and Exercise for Chronic Widespread Pain. Annals of the Rheumatic Diseases, 2013, 72, A131.1-A131.	0.5	0
286	O23. The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. Rheumatology, 2014, 53, i38-i38.	0.9	0
287	39. Non-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. Rheumatology, 2014, 53, i70-i70.	0.9	0
288	Response to: â€~The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis' by González-Gayet al. Annals of the Rheumatic Diseases, 2014, 73, e28-e28.	0.5	0

#	Article	IF	CITATIONS
289	Biologics registers in rheumatoid arthritis. Medicine, 2014, 42, 262-265.	0.2	Ο
290	221. Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour Necrosis Factor Alpha Inhibition. Rheumatology, 0, , .	0.9	0
291	220. Predicting Successful Long-Term Treatment with Tumour Necrosis Factor Alpha Inhibitors in Patients with Psoriatic Arthritis. Rheumatology, 0, , .	0.9	Ο
292	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	0.9	0
293	Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?. Rheumatology, 2017, 56, kew466.	0.9	0
294	Reply. Arthritis and Rheumatology, 2017, 69, 2402-2403.	2.9	0
295	054. TREATMENT DECISIONS FOLLOWING A DIAGNOSIS OF CANCER DURING TUMUOR NECROSIS FACTOR INHIBITOR TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56, .	0.9	Ο
296	212 Multimorbidity is associated with increased disability but lower disease activity over time in patients with RA: results from the BSRBR-RA. Rheumatology, 2018, 57, .	0.9	0
297	243 Longâ€ŧerm risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRâ€RA). Rheumatology, 2018, 57, .	0.9	Ο
298	Epidemiology and health-related services. Current Opinion in Rheumatology, 2002, 14, 87-88.	2.0	0
299	Cardiovascular Risk in Rheumatic Disease. , 2013, , 505-514.		Ο
300	Epidemiologic concepts and classification of rheumatic and musculoskeletal conditions. , 2015, , 1-8.		0
301	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research, 2022, 10, 1-240.	0.4	0